Researchers have identified how young children naturally develop immunity to the bacterial infection Strep A—a breakthrough that could accelerate vaccine development and potentially save up to half a million lives annually, according to a new study.
Understanding the Strep A Threat
Strep A, or Group A Streptococcus, is a widespread bacterium responsible for mild illnesses like sore throat and skin infections. However, in severe cases, it can cause life-threatening diseases. While deaths from Strep A are rare in wealthier nations, thousands in low- and middle-income countries die from the infection each year. A deadly outbreak in the UK and Europe in late 2022 claimed hundreds of lives, including many children.
Tracking Immunity in Gambian Children
In partnership with the Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene and Tropical Medicine, the University of Sheffield team studied how children in The Gambia acquire natural immunity to Strep A. By following participants from birth through early childhood, they mapped the immune response to the bacteria.
Identifying Protective Antibodies
Published in Nature Medicine, the research revealed that infants are born with maternal antibodies that provide short-term protection against Strep A. This immunity fades quickly, but young children rapidly develop their own antibodies after exposure to the bacteria. The scientists pinpointed the specific antibodies linked to protection, highlighting a crucial developmental window for immunity.
Significance for Vaccine Development
Lead author Dr. Alex Keeley, Wellcome Clinical PhD Fellow in Global Health, emphasized that understanding this process eliminates a key barrier to vaccine creation. “For the first time in humans, we have observed how antibodies formed after vaccination could work to prevent infections,” he said.
A Community Perspective
Gambian scientist Fatouamta Camara noted that Strep A imposes a “devastating burden” on communities. It impacts both health outcomes and socio-economic conditions. She stressed that a vaccine could break this cycle and enable children to thrive.
Collaborative Effort Towards Life-Saving Solutions
As reported by The Hindu, the study involved Sheffield’s Florey Institute of Infection. It also included the GSK Vaccine Institute for Global Health. Professor Thushan de Silva, Co-Director of the Florey Institute, underscored the importance of cross-institutional collaboration, stating, “This study reflects the value of working together to deliver high-quality, impactful research in global health.”